Zevra (ZVRA) Q4 2025 earnings review
MIPLYFFA's Surge Drives Zevra to Operational Profitability
Zevra delivered a breakout quarter, reversing its historical cash burn by achieving a $12.2 million Net Income in Q4—without the aid of a PRV sale. This milestone was fueled by an accelerating U.S. launch of MIPLYFFA (arimoclomol), which saw a massive spike in new prescription enrollment forms (24 in Q4 vs. 8 in Q3). With a cash fortress of $238.9 million, Zevra has firmly transitioned from a speculative development biotech to a self-sustaining commercial rare disease company. While the pipeline asset Celiprolol is moving at a crawl and OLPRUVA is effectively dead weight, the sheer cash-generating power of MIPLYFFA easily overshadows these blemishes.
🐂 Bull Case
For the first time since launch, Zevra achieved true operational profitability in Q4 with $12.2M in net income, decoupling the company from reliance on capital markets or one-time PRV sales.
Fears of a 'post-EAP cliff' (a drop-off after initially converting clinical trial patients) were shattered. Q4 brought in 24 new prescription enrollment forms, tripling the Q3 pace and indicating deep penetration into the unaddressed market.
🐻 Bear Case
Zevra's valuation is completely tethered to MIPLYFFA. OLPRUVA has structurally failed in the UCD market, leaving the company with little commercial diversification.
The Phase 3 DiSCOVER trial for Celiprolol has only reached 52 patients and 1 confirmed clinical event. The timeline to actionable data appears exceptionally long, eroding the present value of the pipeline.
⚖️ Verdict: 🟢
Bullish. The math speaks for itself: an accelerating topline ($34.1M), shrinking R&D ($2.6M), and crossing the threshold into recurring profitability. The execution on the MIPLYFFA launch is top-tier.
Key Themes
MIPLYFFA Prescription Enrollments Accelerating
The core metric for Zevra’s future is new patient starts. In Q2 and Q3, new enrollment forms decelerated to a stable 7 and 8 per quarter, raising concerns about market saturation. Q4 completely reversed this trend with 24 new enrollments. This acceleration is likely driven by management's investments in AI-driven data analysis of EMR/medical records and genetic testing initiatives, actively diagnosing new patients rather than just picking low-hanging fruit.
European Expansion Nearing an Inflection Point
Zevra is targeting an estimated 1,100 Niemann-Pick disease type C (NPC) patients in Europe. The EMA has issued its 120-day list of questions, placing the MAA review firmly on track. Crucially, Zevra has seeded the market with 113 patients globally through an Expanded Access Program (EAP). This guarantees instant revenue conversion upon local reimbursement approvals, mirroring the explosive U.S. launch dynamic.
Celiprolol Development Remains Sluggish
While management touts progress across their pipeline, the data contradicts the enthusiasm. The Phase 3 DiSCOVER trial for Vascular Ehlers-Danlos Syndrome (VEDS) only added 8 patients in Q4, bringing the total to 52. Because it is an event-driven trial requiring 28 events for interim analysis—and only 1 event has been confirmed thus far—the timeline to commercialization is severely delayed.
OLPRUVA is a Definitively Failed Asset
Despite previous strategic pivots to target niche UCD patient segments (adults/OTC deficient), the drug generated a minuscule $0.4M in Q4 (and only $0.8M for the full FY25). This is stable, dead-bottom performance. Following a $58.7M impairment charge in Q2 2025, investors should strip OLPRUVA out of their valuation models entirely.
Opex Structure Shift Complete
Zevra has fundamentally transformed its cost structure. R&D spending decelerated dramatically from $42.1M in FY24 to just $12.7M in FY25, following the completion of the KP1077 trial. Meanwhile, SG&A has stepped up to $77.6M to support commercialization. Moving the global headquarters to Boston signals an intent to build a premier commercial and executive talent hub for a mature bio-pharma footprint.
Regulatory & Macro Dynamics Influencing Net Revenue
While volume growth is stellar, Zevra is navigating the complexities of U.S. payer structures. As noted in prior quarters, the Medicare Part D redesign (where catastrophic phase rebates shifted significantly) created gross-to-net variability. Maintaining high net realized pricing will remain a key macro/regulatory headwind as payer mix evolves.
Other KPIs
An exceptionally strong balance sheet profile. Zevra ended the year with $238.9M in cash, equivalents, and securities, up massively from $75.5M at the end of 2024. Fueled by the Q2 $150M PRV sale and accelerating operational cash generation, dilution risk is functionally zero for the foreseeable future.
Stable. Gross margins on MIPLYFFA are incredibly high. Total COGS (excluding intangible amortization) was only $1.5M against $34.1M in net revenue, highlighting the massive operating leverage inherent in this rare disease model.
Decelerating. Down from $8.4M in the prior year quarter. Zevra is currently running a very lean development organization, keeping cash flow elevated but potentially raising questions about the depth of the early-stage pipeline behind Celiprolol.
Guidance
Management reiterated that their current operating forecast combined with the $238.9 million war chest provides sufficient financial flexibility to execute all strategic priorities without raising additional equity.
Key Questions
Payer Mix and Gross-to-Net
With the massive spike of 24 new patient enrollments in Q4, how has the payer mix shifted between Commercial and Medicaid/Medicare, and what impact will this have on gross-to-net margins in 2026?
European Go-To-Market Strategy
As the EMA review approaches its later stages, what is the definitive commercialization strategy for Europe? Are you planning to build an internal footprint, or out-license to a regional partner to avoid bloating SG&A?
Celiprolol Alternatives
Given the very slow event generation (only 1 confirmed event) and enrollment pace (52 of 150) in the DiSCOVER trial, are you considering amending the trial protocol or exploring strategic alternatives for the asset?
Capital Allocation
Now that you are generating positive operational net income and sitting on nearly $240 million in cash, how are you viewing M&A or in-licensing opportunities to diversify the pipeline beyond MIPLYFFA?